Seres Therapeutics has presented interim results from an ongoing Phase II trial which has sent company stock spiralling downward, as …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

